Related Experiment Video

Updated: Feb 2, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.8K

Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint

Bushra Kanwal1, Sharmi Biswas2, Robert S Seminara3

  • 1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Cureus
|November 13, 2018
PubMed

Insights

Immunotherapy targeting immune checkpoints shows promise for non-small cell lung cancer (NSCLC). Combining immunotherapy with chemotherapy may improve outcomes for various patient subgroups, warranting further large-scale trials.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immunotherapy has shown moderate success in cancer treatment over decades.
  • Immune checkpoint inhibitors are effective in various tumors, including metastatic non-small cell lung cancer (NSCLC).
  • Current response rates for immune checkpoint inhibitors in metastatic NSCLC are below 20%, necessitating combination therapies.

Purpose of the Study:

  • To review the potential clinical benefits of immunotherapy alone or in combination with chemotherapy in NSCLC.
  • To explore the role of chemotherapy as a partner treatment to enhance antitumor immune activity.

Main Methods:

  • Review of existing primary research and clinical trial data.
  • Analysis of immunotherapy and chemotherapy combination protocols for different NSCLC patient subgroups.

Main Results:

  • Immune checkpoint inhibitors offer long-lasting responses in a subset of metastatic NSCLC patients.
  • Chemotherapy can modulate the immune response, potentially enhancing immunotherapy efficacy.
  • Preliminary studies show promising results for combining immunotherapy and chemotherapy in metastatic NSCLC.

Conclusions:

  • Combinational treatment protocols are needed to improve response rates in NSCLC.
  • Further large-scale trials are required to validate the efficacy of immunotherapy combined with chemotherapy.
  • Immunotherapy holds appeal for both metastatic and nonmetastatic NSCLC cases.
Keywords:
atezolizumabchemotherapyimmune checkpoint inhibitorsimmunotherapynivolumabnon-small cell lung cancernsclcpd-1 inhibitorpd-l1 inhibitorpembrolizumab

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.0K

Related Concept Videos

The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
783
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups


Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
29.9K